At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 26 enrolled

Drug / intervention

Lenalidomide +1 moredrug

Likely dose

Lenalidomide 25 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01698801

NCT01698801Phase 2Completed

A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma

Celgene·interventional·Posted Oct 3, 2012·Updated Nov 8, 2018

In Brief

A Phase 2 clinical trial evaluating Lenalidomide and dexamethasone for Multiple Myeloma. Completed, enrolled 26 participants across 24 sites.

To determine the efficacy of lenalidomide in combination with low-dose dexamethasone in Japanese subjects with previously untreated multiple myeloma.

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

CountriesJapan

Collaborators--

Phase 2CompletedFinished

20132014201520162017201820192020202120222023202420252026

Enrollment StartOct 2012

First PostedOct 2012

Primary CompletionNov 2013

Study CompletionJun 2018

TodayJul 2026

First PostedOct 3, 2012

Enrollment StartOct 1, 2012

Primary CompletionNov 26, 2013

Study CompletionJun 26, 2018

TodayJul 2, 2026

Enrollment to primary: 1.2 yearsPosted 13.7 years ago

Lenalidomidedrug

25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle

dexamethasonedrug

40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle